There is an increasing prescription of psychotropic medications to youth. This use is accompanied by a developing, but lagging, evidence base for this use. These agents predominantly interact with regulatory neurotransmitters, which have known functions in the developing embryo. This article reviews major diagnostic categories in regards to the biological basis of the mainstays of pharmacology for each condition. Adverse events also are discussed in regards to these common psychopharmacological agents. There is growing evidence that the consequences of not treating serious psychiatric illnesses outweigh known risks of the medications. Prescription practices should endeavor to limit adverse consequences whenever possible.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pcl.2006.05.012 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!